Dr. Ashley Wilson

Dr. Ashley Wilson is a board-certified medical oncologist specialising in haematological malignancies and solid tumour immunotherapy. She earned her medical degree from the University of Chicago Pritzker School of Medicine and completed haematology-oncology fellowship at Memorial Sloan Kettering Cancer Center, developing subspecialty expertise in lymphoma, myeloma, and the emerging field of cancer immunotherapy across tumour types.

Dr. Wilson's clinical focus is the management of Hodgkin's and non-Hodgkin's lymphomas, multiple myeloma, and high-grade solid tumours including lung, melanoma, and renal cell carcinoma. She has particular expertise in the use of checkpoint inhibitor immunotherapy — anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents — both as monotherapy and in combination regimens, and manages the immune-related adverse events that may complicate immunotherapy treatment across multiple organ systems.

She is a site investigator for multiple phase I and II clinical trials evaluating novel immunotherapy combinations, bispecific antibodies, and CAR-T cell therapy for relapsed or refractory lymphoma and myeloma. Her translational research programme investigates tumour microenvironment features that predict response to immunotherapy, with publications in Blood, the Journal of Clinical Oncology, and Cancer Cell.

Dr. Wilson is committed to making participation in clinical trials accessible to all patients, not just those at major academic centres, and advocates for community oncology partnerships that enable rural and underserved patients to access cutting-edge treatments. She brings warmth and directness to difficult conversations about cancer diagnosis and prognosis, and has been recognised by her department with the Excellence in Compassionate Care Award for her extraordinary dedication to patients navigating complex haematological malignancies.